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Background. Imaging Somatostatin Subtype Receptor 2 (SST2) expressing macrophages by
[DOTA,Tyr3]-octreotate (DOTATATE) has proven successful for plaque detection. DOTA-
JR11 is a SST2 targeting ligand with a five times higher tumor uptake than DOTATATE, and
holds promise to improve plaque imaging. The aim of this study was to evaluate the potential of
DOTA-JR11 for plaque detection.
Methods and Results. Atherosclerotic ApoE2/2 mice (n = 22) fed an atherogenic diet were
imaged by SPECT/CT two hours post injection of [111In]In-DOTA-JR11 (* 200 pmol,
* 50 MBq). In vivo plaque uptake of [111In]In-DOTA-JR11 was visible in all mice, with a
target-to-background-ratio (TBR) of 2.23 ± 0.35. Post-mortem scans after thymectomy and
ex vivo scans of the arteries after excision of the arteries confirmed plaque uptake of the
radioligand with TBRs of 2.46 ± 0.52 and 3.43 ± 1.45 respectively. Oil red O lipid-staining and
ex vivo autoradiography of excised arteries showed [111In]In-DOTA-JR11 uptake at plaque
locations. Histological processing showed CD68 (macrophages) and SST2 expressing cells in
plaques. SPECT/CT, in vitro autoradiography and immunohistochemistry performed on slices
of a human carotid endarterectomy sample showed [111In]In-DOTA-JR11 uptake at plaque
locations containing CD68 and SST2 expressing cells.
Conclusions. The results of this study indicate DOTA-JR11 as a promising ligand for
visualization of atherosclerotic plaque inflammation. (J Nucl Cardiol 2020)
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Abbreviations
SST2 Somatostatin subtype receptor 2
SPECT Single photon emission tomography
CT Computed tomography
ORO Oil red O
CEA Carotid endarterectomy
TBR Target-to-background-ratio
INTRODUCTION
Cardiovascular disease is the leading cause of death
worldwide.1 Most cardiovascular events are caused by
atherosclerosis, in which plaques form over time due to
continuous inflammation and lipid deposition in the
arterial wall. Current imaging techniques focus on
plaque morphology or measures such as calcium score,
which are used for cardiovascular risk assessment to
improve clinical risk scores.2 Inflammation is a crucial
factor in atherosclerotic plaque and plays a crucial role
in plaque initiation, progression, and destabilization.3,4
Imaging plaque inflammation may complement tradi-
tional imaging methods, providing a better risk
stratification of patients at risk of future cardiovascular
events.
2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) has
proven a reliable non-invasive imaging method not only
to detect, but even to quantify the degree of inflamma-
tion in plaques.5–7 18F-FDG, therefore, provides a
valuable tool to assess and monitor disease burden.8
However, background uptake in normal tissue and high
uptake of 18F-FDG in the myocardium severely hinders
detection of coronary plaques,9,10 and warrants the
search for novel radioligands.
Somatostatin Subtype Receptor 2 (SST2) is highly
expressed on activated macrophages.11,12 As macro-
phages are the main inflammatory cell type in
atherosclerotic plaque, SST2 has been proposed as a
relevant imaging target for inflammation-based plaque
detection. A number of studies have reported on the use
of SST2 for inflammation-based imaging of atheroscle-
rosis.13–19 Moreover, Tarkin et al. recently prospectively
validated [68Ga]Ga-[DOTA, Tyr3]-octreotate (DOTA-
TATE) as a marker for plaque inflammation 20 in a
clinical study. They demonstrated the feasibility to
detect both carotid and coronary plaques with [68Ga]Ga-
DOTATATE. Moreover, [68Ga]Ga-DOTATATE could
better discriminate between high-risk and low-risk
lesions compared to [18F]FDG.
Various radioligands, based on SST2 agonists, for
SST2-targeted imaging and therapy have been developed
and used over the past 20 years for detection and
treatment of SST2-expressing tumors.
21 More recently, a
new generation of radioligands based on SST2 antago-
nists has been developed and described, showing more
favorable pharmacokinetics and higher tumor uptake
than agonists like DOTATATE. Of these, the compound
JR11 (Cpac[D-Cys-Aph(Hor)-D-Aph(Cbm)-Lys-Thr-
Cys]-D-Tyr-NH2) performed best in preclinical and
clinical studies as an imaging as well as a therapeutic
agent.21–24 Based on the reported favorable biodistribu-
tion and targeting efficiency of DOTA-JR11, we studied
the potential of DOTA-JR11 in inflammation imaging
for atherosclerotic plaque detection as it could yield
higher TBRs than agonistic radioligands. We therefore
used [111In]In-DOTA-JR11 Single Photon Emission
Computed Tomography/Computed Tomography
(SPECT/CT) to image plaques in vivo in an atheroscle-
rotic mouse model, and assessed target binding in
human plaque material.
MATERIALS AND METHODS
Animals and Experimental Setup
Atherosclerotic female ApoE-/- mice on a C67BL/6J
background (n = 22) were purchased from Charles Rivers
(Calco, Italy) at 6 weeks of age, and were fed a high fat diet
(0.3% cholesterol, Altromin Spezialfutter GmbH & Co. KG,
Lage, Germany) ad libitum from an age of 8 weeks up to
20 weeks. All animal experiments were approved by the
institutional animal studies committee and were in accordance
with Dutch animal ethical legislation and the European Union
Directive.
Radiolabeling
[111In]In-DOTA-JR11 (MW = 1690 g/mol) (kindly pro-
vided by Dr. Helmut Maecke) was radiolabeled with
[111In]InCl3 (Covidien, Petten, The Netherlands) with a speci-
fic activity of 200 MBq/nmol as described previously.25
Radiochemical purity ([ 95%) and incorporation yield
([ 99%) were evaluated with high-pressure liquid chromatog-
raphy and instant thin-layer chromatography on silica gel.
Quenchers (3.5 mM gentisic acid, 3.5 mM ascorbic acid, 7%
ethanol) were added to prevent radiolysis as described
previously.26
In Vivo Imaging and Validation
Mice (n = 22) were injected with 50 MBq/200 pmol
[111In]In-DOTA-JR11 in Phosphate Buffered Saline (PBS)
with 0.1% Bovine Serum Albumin (BSA), with a total
injection volume of 150 lL. Four mice were co-injected with
a 100 9 excess of unlabeled DOTA-JR11 to test the specificity
of the radioligand. Mice were anesthetized with 1.5%
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isofluorane 2 hours post injection, after which they were
injected with 50 lL CT-contrast agent (Exitron Nano 12000,
Milteny Biotec, Bergisch-Gladbach, Germany). Immediately
after contrast agent injection, mice were transferred to a
VECTor5/CT scanner (MILabs B.V. Utrecht, The Nether-
lands) on which a CT scan was made followed by a SPECT
scan. The time between radioligand injection and imaging was
based on pilot experiments (data not shown). The CT scan was
made with the following settings: full scan angle; accurate scan
mode; 50 kV tube voltage; 0.24 mA tube current; 3.5 minute
scan time. CT scans were reconstructed at a resolution of
80 lm. SPECT was performed with the M3.0 pinhole colli-
mator (resolution\ 1.3 mm, sensitivity[ 30,000 cps/MBq).
Data were acquired in list-mode using the following acquisi-
tion parameters: 1 h scan; 15 positions; spiral scan mode; fine
step mode. Scans were reconstructed with energy windows
incorporating a width of 20% of the In-111 photo peaks of 171
and 245 keV with background windows of 2.5% on either side
of the photo peak windows, and scatter correction was applied
according to Ref. 27 Reconstructions were performed with a
SROSEM (Similarity Regulated Ordered Subset Expectation
Maximization28) algorithm with 9 iterations, 128 subsets, with
a voxel size of 0.4 mm and a post reconstruction 3-dimen-
sional Gaussian filter was applied (1 mm full width at half
maximum).
After in vivo imaging, mice were euthanized with an
overdose of isoflurane, after which the vasculature was flushed
with PBS via the left ventricle, and thymectomy was
performed. In this state, the thorax of the euthanized mice
was scanned ‘in situ’ to circumvent signal interference from
thymic uptake of [111In]In-DOTA-JR11 with signal from
plaque uptake. CT and SPECT settings for in situ imaging
were the same as for in vivo imaging, except for a shorter
SPECT scan duration of 30 minutes.
The arteries were removed after in situ imaging, and
cleaned of remaining connective tissue. They were then stained
for lipids (Oil Red O (ORO) according to standard protocol) to
confirm plaque presence, and scanned ex vivo with SPECT/
CT. The scan settings for ex vivo imaging were the same as
in situ settings except for four SPECT positions due to a
smaller field of view. Subsequently, the arteries were cut open
and used for ex vivo autoradiography (n = 4) or embedded in
Tissue-Tek O.C.T. compound (Sakura Finetek Europe B.V.,
Alphen aan den Rijn, The Netherlands) and stored at – 80 C
for histological analysis (n = 14). After * 2 weeks, arteries
used for ex vivo autoradiography were placed on a phosphor
screen overnight and read using a phosphor imager (Cyclone,
Perkin Elmer).
Ex vivo Carotid Endarterectomy Study
To investigate binding of [111In]In-DOTA-JR11 to and its
potential for imaging of human plaque tissue, we performed an
ex vivo study with human carotid endarterectomy (CEA) tissue
slices. For this purpose we sliced a CEA sample (acquired with
informed consent and approved by the medical ethics com-
mittee of the Erasmus MC, MEC 2008-147) into 2 mm slices.
Even-numbered slices were embedded in O.C.T. compound
and stored at - 80 C for later in vitro binding assays and
histological evaluation. Odd-numbered slices were incubated
with 200 MBq/1 nmol [111In]In-DOTA-JR11 in 20 mL PBS
with 0.1% BSA for one hour. After incubation, the slices were
washed in PBS with 0.1% BSA until no residual radioactivity
remained in the washing medium as measured by a dose
calibrator (Dose calibrator VDC-405, Comecer Netherlands,
Joure, The Netherlands). The slices were subsequently placed
on a holder, and imaged with the VECTor5/CT. CT and
SPECT settings were the same as for the in vivo mouse scan,
except a mouse 1.6 pinhole collimator (resolution\ 1.6 mm,
sensitivity[ 1500 cps/MBq) was used with 38 scan positions,
and the scans were reconstructed with a Gaussian filter of
0.5 mm full width at half maximum.
Immunohistochemistry and In Vitro
Binding Assays
Embedded mouse arteries and CEA slices were sectioned
into 5 lm sections, which were immunohistochemically
stained for CD68 (Mouse: 1:100, Biorad, MCA1848; human:
1:100, Abcam, ab955) and SST2 (1:100, Abcam, clone UMB-
1) to assess target presence and presence of macrophages. In
short, sections were fixed in cold acetone for 5 minutes,
endogenous peroxidase was blocked with 0.3% H2O2, and non-
specific binding was blocked with 1% BSA for mouse CD68
staining and 2% normal goat serum for SST2 and human CD68
staining. The primary antibody was omitted from the protocol
in negative controls.
10 lm sections, adjacent to the 5 lm sections used for
immunohistochemistry, were cut from the embedded CEA
slices to assess radioligand uptake via an in vitro competition
binding assay (autoradiography). Sections were incubated for
1 h with 10-9 M [111In]In-DOTA-JR11 with or without an
excess of 10-6 M unlabeled DOTA-JR11 to asses specific
binding. Slides were exposed to phosphor screens overnight
and read with a phosphor imager (Cyclone, Perkin Elmer).
Haematoxylin–eosin staining according to standard protocol
was performed on the sections afterwards.
Quantification and Statistics
SPECT/CT data were analyzed with Vivoquant (Invicro)
by quantification of the activity within manually drawn regions
of interests (ROIs) based on contrast-enhanced CT images. In
vivo ROIs were drawn for the aortic arch and the brachio-
cephalic artery, whereas the vena cava inferior and jugular vein
were used as background regions. In situ ROIs were the aortic
arch and brachiocephalic artery, and the heart ventricles were
taken as background tissue. ROIs on ex vivo images were also
the aortic arch and brachiocephalic artery for plaque areas, and
the relatively healthy descending thoracic aorta as background.
Target-to-background-ratios (TBRs) were calculated and
expressed as mean ± standard deviation.
In vitro autoradiography analysis was performed by
drawing ROIs around tissue sections in Optiquant (Perkin
Elmer), quantifying the signal as Digital Light Units (DLU)/
mm2 and comparing non-blocked to blocked tissue sections.
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The Shapiro–Wilk test was used to test data for normality.
The student’s t test was used to compare means of normally
distributed data, the Mann–Whitney U test was used for non-
parametric data.
RESULTS
Mouse Plaque Imaging
In vivo SPECT/CT imaging 2 h after intravenous
injection of [111In]In-DOTA-JR11 showed focal uptake
at locations of plaque formation in the vasculature of all
animals (Fig. 1A-D), with an average TBR of
2.23 ± 0.35. Thymic uptake (average TBR of
2.28 ± 0.51) of [111In]In-DOTA-JR11 masked plaque
signal and therefore complicated visualization and
quantification. Therefore, ‘in situ’ scans were made in
post-mortem thymectomized animals. In situ SPECT/CT
imaging confirmed plaque uptake of [111In]In-DOTA-
JR11 as seen in in vivo images (Fig. 1E-H), with a TBR
of 2.46 ± 0.52. Blocking studies with an 100x excess of
DOTA-JR11 significantly reduced the arterial signal
(TBR in vivo blocked: 1.47 ± 0.36; TBR in situ
blocked: 1.36 ± 0.15, P = 0.05, see Fig. 1I and Online
Resource 1) Likewise, blocking significantly reduced
uptake in the thymus (TBR 1.32 ± 0.43, P = 0.05).
Presence of plaque in excised arteries was con-
firmed by ORO staining of excised arteries. Ex vivo
SPECT/CT imaging of the mouse arteries showed
uptake of [111In]In-DOTA-JR11 at plaque locations in
the aortic arch and brachiocephalic artery with a TBR of
3.43 ± 1.45 (Fig. 1J). Ex vivo autoradiography and
ORO staining of excised, cut open arteries confirmed
uptake of [111In]In-DOTA-JR11 in plaque (Fig. 2A, B).
Immunohistochemistry of the arteries confirmed pres-
ence of SST2 and CD68 expressing cells in plaque
(Fig. 2C-F).
Human Plaque Imaging
Two millimeter thick slices of a human carotid
endarterectomy sample incubated with [111In]In-DOTA-
JR11 showed focal hotspots of radioligand uptake
detectable by SPECT, reflecting the presence of SST2
as determined by immunohistochemistry (Fig. 3).
Fig. 1. [111In]In-DOTA-JR11 uptake in mouse atherosclerotic plaque two hours post injection of
200 pmol [111In]In-DOTA-JR11. A Sagittal CT, B saggital SPECT/CT, C coronal CT, and D
coronal SPECT/CT image of [111In]In-DOTA-JR11 uptake in vivo in an atherosclerotic mouse. E
Sagittal CT, F saggital SPECT/CT, G coronal CT, and H coronal SPECT/CT image of [111In]In-
DOTA-JR11 uptake in situ in the mouse displayed in (A-C) scanned post-mortem after thymectomy
and flushing of the vasculature with PBS. I Sagittal SPECT/CT image of a mouse two hours post
injection of 50 MBq/200 pmol [111In]In-DOTA-JR11 plus a 100 9 excess of unlabeled DOTA-
JR11. Plaque uptake was strongly reduced by blocking. J Maximum intensity projection image of
the excised arteries of the mouse shown in (A-H). Focal uptake of [111In]In-DOTA-JR11 is visible
at the plaque location. Arrowheads indicates the location of the aortic arch containing plaque,
arrows indicates thymic uptake of [111In]In-DOTA-JR11, *Indicates uptake in the liver, H indicates
the heart.
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Noticeably, no radioligand uptake or SST2 expression
was visible in areas of macrocalcifications visible in CT.
In vitro autoradiography performed on 10 lm sections
of adjacent 2 mm slices showed specific binding of
[111In]In-DOTA-JR11 when compared to adjacent sec-
tions incubated with a 1000 9 excess of unlabeled
DOTA-JR11 (non-blocked = 35 9 106 ± 90 9 105,
blocked = 25 9 106 ± 63 9 105 DLU/mm2, P = 0.005,
see Online Resource 2 and Fig. 3). Moreover, radioli-
gand uptake visualized on in vitro autoradiography co-
localized with CD68 and SST2 expression on adjacent
sections, and signal as seen on the SPECT/CT images of
the adjacent 2 mm slices (Fig. 3B-E).
Fig. 2. A Excised, cut open and Oil red O stained arteries of a mouse injected with 200 pmol
[111In]In-DOTA-JR11. Scale bar indicates 2 mm. B Matching high resolution ex vivo autoradio-
gram to the arteries shown in (A), showing [111In]In-DOTA-JR11 uptake at plaque locations. C, D
show immunohistochemistry for CD68 (macrophages) and Somatostatin Subtype Receptor 2
(SST2) expressing cells in mouse plaque, respectively. Scale bar indicates 100 lm. E, F show the
overview of the histological sections shown in (C) and (D); the asterisk marks the location of the
zoomed area in (C) and (D). Scale bar indicates 2.5 mm.
Fig. 3. [111In]In-DOTA-JR11 uptake in human carotid endarterectomy (CEA) tissue after
incubation with [111In]In-DOTA-JR11. A Transverse SPECT/CT image of a 2 mm slice of a
CEA sample. Calcifications are visible in CT in white, the asterisk indicates the holder used to keep
the 2 mm slice in place. B, C In vitro autoradiography of adjacent 10 lm sections made of an
adjacent 2 mm slice of the same CEA sample seen in (A). The section in B was incubated with
10-9 M [111In]In-DOTA-JR11, the section in C was incubated with 10-9 M [111In]In-DOTA-JR11
plus a blocking dose of 10-6 M unlabeled DOTA-JR11. The inset shows the boxed region at higher
magnification, the red arrows indicate sectioning artifacts (tissue folds). D SST2 and E CD68
immunohistochemistry on 5 lm sections adjacent to B and C, with matching insets. Scale bar
indicates 2 mm.
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DISCUSSION
We have demonstrated the feasibility of imaging
atherosclerotic plaques by targeting SST2 with DOTA-
JR11, by visualizing plaque with In-111 labeled DOTA-
JR11 in a mouse model of atherosclerosis and in human
plaque tissue. We showed that radioligand uptake is
located in plaque regions in the mouse vasculature as
evidenced by in vivo and in situ SPECT/CT imaging,
autoradiography, and ORO staining. [111In]In-DOTA-
JR11 uptake in human plaque tissue co-localizes with
SST2 and CD68 expressing cells, whereas blocking
studies show target-specific uptake in vivo and in situ in
mouse plaque, and in vitro in human tissue.
High thymic uptake of [111In]In-DOTA-JR11, vis-
ible in the in vivo SPECT images and in line with
reported SST2 expression in mice in this tissue,
29 is
problematic when visualizing plaque in the used
atherosclerotic model. Nevertheless, we demonstrated
that the in vivo signal visible next to the thymus did
originate from plaque, by comparing the intensity and
the localization of plaque signal in the in vivo, in situ,
and ex vivo SPECT scans, as well as the ex vivo
autoradiography. Thymic uptake is not expected to
interfere with human plaque imaging as thymic activity
wanes during adolescence, and little SST2-ligand bind-
ing has been found in dedicated studies.30 Ex vivo
imaging of a human CEA sample showed that SPECT
imaging using [111In]In-DOTA-JR11 is feasible in
human plaque tissue and that radioligand uptake co-
localizes to regions of inflammation as evidenced by
CD68 and SST2 immunohistochemistry. These results
indicate that DOTA-JR11 has potential for imaging of
inflammation in human plaques.
Oncological studies reported a five times higher
uptake of DOTA-JR11 over DOTATATE in SST2
positive tumors.21–23 It is hypothesized that antagonistic
ligands such as DOTA-JR11 have more binding sites on
the receptor than agonistic ligands such as DOTA-
TATE.31 Although the exact mechanism for this
difference in uptake remains to be elucidated, the
growing amount of studies using SST2-mediated imag-
ing in atherosclerosis 13–19 indicate DOTA-JR11 as an
interesting candidate for further studies.
DOTATATE and DOTA-JR11 have not been com-
pared for the detection of atherosclerotic plaque. Two
preclinical studies have tested [68Ga]Ga-DOTATATE
for plaque imaging in mouse models, however.
Although it is difficult to compare studies using different
animal models and different imaging systems, the results
found in 14,15 indicate that [68Ga]Ga-DOTATATE has a
lower TBR compared to [111In]In-DOTA-JR11 in our
study. Rinne et al. found an aorta to blood ratio of
0.67 ± 0.04 using [68Ga]Ga-DOTATATE in vivo in
IFG-II/LDLR-/-ApoB100/100 mice,15 indicating low
radioligand uptake in plaque. However, they also
reported a high plaque to wall ratio of 2.1 ± 0.5 for
[68Ga]Ga-DOTATATE in autoradiographic studies. Li
et al. found a similar plaque to non plaque ratio
of * 1.8 after autoradiographic analysis of ApoE-/-
arteries incubated with [68Ga]Ga-DOTATATE.14 We
found an in vivo TBR of 2.23 ± 0.35 and an in situ TBR
of 2.46 ± 0.52, and in the autoradiogram of the mouse
arteries we found a TBR of 3.43 ± 1.45. Taken together,
these studies warrant further investigations into the
added value of DOTA-JR11 over DOTATATE in
atherosclerotic patients.
If a five times higher uptake of DOTA-JR11, as was
found in oncological studies, would be found in
atherosclerosis as well, DOTA-JR11 could offer possi-
bilities for visualization of less inflamed plaques or
plaques with lower SST2 expression. Moreover, the
DOTA chelator of JR11 allows labeling with different
radionuclides including Ga-68, making DOTA-JR11
attractive for PET imaging. Although different
radiometals result in differences in binding affinity of
DOTA-JR11,32 the attractive pharmacokinetics of
DOTA-JR11 are conserved when labeled with Ga-68.24
Because inflammation in different plaque regions
can have a substantial effect on the rupture risk of
atherosclerotic plaques, future studies should investigate
whether DOTA-JR11 uptake can be correlated to dif-
ferent plaque phenotypes. A better interpretation of
radioligand uptake related to plaque phenotype could be
a major step in patient risk stratification.
CONCLUSION
Our results indicate DOTA-JR11 as a promising
ligand for atherosclerosis imaging based on our promis-
ing in vivo results and ex vivo validation studies.
DOTA-JR11 could be a valuable improvement in
imaging of inflammation in atherosclerotic disease.
NEW KNOWLEDGE GAINED
The SST2 targeting radioligand [
111In]In-DOTA-
JR11 can be used to detect plaques in a mouse model of
atherosclerosis by visualizing plaque inflammation.
[111In]In-DOTA-JR11 uptake in human plaque tissue
indicates the translational potential of this radioligand
for human imaging. Recent success of SST2 imaging in
atherosclerosis with DOTATATE, and a five times
higher TBR of DOTA-JR11 than DOTATATE in
oncological studies, make DOTA-JR11 an interesting
ligand for further studies in atherosclerosis.
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